Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, June 7, 2016

Public edition | newswise.com

Newswise Cancer Research Wire for 07-Jun-2016
FacebookTwitterLinkedInStumbleupon

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

New Approach to MRI Imaging Links Saturated Fats to Breast Cancer in Postmenopausal Women

High saturated fats in breast tissue may be an indicator of cancer in postmenopausal women, study shows.

(Embargo expired on 07-Jun-2016 at 00:00 ET)

journal of the Radiological Society of North America; R01-CA160620

– NYU Langone Medical Center

New Chemical 'Sponges' Designed to Soak Up Toxic Cancer-Fighting Drugs After Targeting Tumors

Researchers at Berkeley Lab are developing and testing materials for a new device that can be inserted via a tiny tube into a vein and soak up cancer-fighting drugs after they deliver a dose to tumors—and before they can widely circulate in the body.

 • Image(s) embedded • 

Journal of Medical Devices, December 2014

– Lawrence Berkeley National Laboratory

Study Questions Cancer Link with Bone Growth Factor for Spinal Surgery

Adding to previous evidence, a study based on a statewide cancer database shows no increase in cancer risk in patients undergoing spinal fusion surgery with the bone-promoting growth factor recombinant human bone morphogenetic protein (rhBMP). The study appears in Spine, published by Wolters Kluwer.

Spine

– Wolters Kluwer Health: Lippincott Williams and Wilkins

Novel Imaging Model Helps Reveal New Therapeutic Target for Pancreatic Cancer

Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. In a new study, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University, the University of Nebraska and Ionis Pharmaceuticals describe an innovative new model that not only allowed them to track drug resistance <i>in vivo</i>, but also revealed a new therapeutic target.

 • Video / Image(s) embedded •  (Embargo expired on 06-Jun-2016 at 11:00 ET)

Nature

– University of California, San Diego Health Sciences

Pembrolizumab Elicits Significant Antitumor Activity in Advanced Head and Neck Cancer Patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial.

(Embargo expired on 06-Jun-2016 at 12:30 ET)

ASCO

– Perelman School of Medicine at the University of Pennsylvania

Combo Immunotherapy for Advanced Melanoma: Two Therapies may be Better Than One

A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one: One treatment uses a patient’s own T cells modified in the lab to more powerfully recognize and attack tumors; The other treatment, a “checkpoint inhibitor,” releases the brakes on the body’s natural immune system.

(Embargo expired on 06-Jun-2016 at 16:00 ET)

Journal of Clinical Oncology

– Fred Hutchinson Cancer Research Center

Nivolumab Extends Survival for Patients with Advanced Kidney Cancer Treated Beyond Disease Progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.

(Embargo expired on 06-Jun-2016 at 07:30 ET)

American Society of Clinical Oncology (ASCO) 52nd Annual Meeting

– Roswell Park Cancer Institute

Increase in Obesity Among Pediatric Hodgkin Lymphoma Patients May be Linked to Disease Relapse

A study led by researchers at Roswell Park Cancer Institute and Columbia University Medical Center used advanced imaging methods to evaluate obesity, and suggests a relationship between obesity and disease relapse.

(Embargo expired on 06-Jun-2016 at 07:30 ET)

American Society of Clinical Oncology (ASCO) 52nd Annual Meeting

– Roswell Park Cancer Institute

Cancer Diagnosed More Often in Patients with Primary Immunodeficiency Diseases

Roswell Park researchers evaluated the overall and site-specific incidence of cancer among patients registered in USIDNET, and found increased cancer incidence rates, especially in lymphomas, among patients with primary immunodeficiency diseases.

(Embargo expired on 06-Jun-2016 at 07:30 ET)

American Society of Clinical Oncology (ASCO) 52nd Annual Meeting

– Roswell Park Cancer Institute

T-Cell Receptor Sequencing Reveals Novel Biomarkers for Ovarian Cancer

Researchers used deep T-cell receptor (TCR) sequencing to evaluate the clonal composition of tumor-infiltrating lymphocytes, or TILs, and identify novel prognostic biomarkers in ovarian cancer.

(Embargo expired on 06-Jun-2016 at 07:30 ET)

American Society of Clinical Oncology (ASCO) 52nd Annual Meeting

– Roswell Park Cancer Institute

Methotrexate Exposure Impacts Cognitive Processes Cancer Survivors Need to Multitask

St. Jude Children’s Research Hospital reports that higher blood concentrations of methotrexate during cancer treatment are associated with brain changes and impaired executive function in survivors of pediatric leukemia.

 • Image(s) embedded •  (Embargo expired on 06-Jun-2016 at 16:00 ET)

MH085849

– St. Jude Children's Research Hospital

Progression-Free Survival Triples in Select Metastatic Lung Cancer Patients with Surgery or Radiation After Standard Chemotherapy

Lung cancer patients with oliogometastases, defined as three or fewer sites of metastasis, may benefit from aggressive local therapy, surgery or radiation, after standard chemotherapy, according to research led by The University of Texas MD Anderson Cancer Center.

 • Image(s) embedded •  (Embargo expired on 06-Jun-2016 at 10:45 ET)

– University of Texas M. D. Anderson Cancer Center

Novel Protein Inhibitors Engineered as Alternative Approach to Potentially Treat Cancer and Other Diseases

Researchers have engineered endogenous protein inhibitors of protein-degrading enzymes as an alternative approach to synthetic inhibitors for potentially treating cancer and other diseases.

 • Image(s) embedded • 

Journal of Biological Chemistry

– Florida Atlantic University

Blood-Born Molecules Could Predict Those Who Will Develop Liver Cancer

A panel of microRNAs from blood samples may predict patients at high risk of developing a common liver cancer from hepatitis B virus infection.

– Thomas Jefferson University

Investigational Immunotherapy Drug Well Tolerated in Those with Rare Form of Melanoma

An investigational immunotherapy drug being tested in the treatment of a rare form of skin cancer known as Merkel cell carcinoma has been found to be well tolerated with a clinical benefit seen in up to 42 percent of patients who failed prior treatment and were observed for at least six months.

 • Image(s) embedded • 

ASCO Annual Meeting 2016

– Rutgers Cancer Institute of New Jersey

Advanced Cancer Patients Receive Aggressive Care at High Rates at the End of Life, UNC Lineberger Study Finds

A national health claims analysis of cancer patients who were younger than age 65 and had metastatic disease revealed that nearly two-thirds were admitted to the hospital or visited the emergency room in the last 30 days of their lives. The researchers said nearly a third of patients died in the hospital.

 • Image(s) embedded • 

ASCO Annual Meeting, June-2016

– University of North Carolina Health Care System

Study May Help Reassure Women Taking Tamoxifen for Breast Cancer

A study presented at ASCO may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.

American Society of Clinical Oncology

– Loyola University Health System

New Method Seeks to Diminish Risk, Maximize Investment in Cancer “Megafunds”

Recognizing the high research and development costs for drugs to combat cancer, a team of researchers has devised a method to maximize investment into these undertakings by spotting which efforts are the most scientifically viable.

Oncotarget

– New York University

Moffitt Cancer Center Researchers Present Phase 1 Study Results of Selinexor Combination Therapy for Multiple Myeloma Patients

TAMPA, Fla. – Moffitt Cancer Center will present results from a phase 1 study of selinexor in combination with liposomal doxorubicin and dexamethasone in patients with relapsed and refractory multiple myeloma. The findings will be discussed Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

– Moffitt Cancer Center

Personalized Medicine Leads to Better Outcomes for Patients with Cancer

In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.

JAMA Oncology

– University of California, San Diego Health Sciences

Personalized Medicine Leads to Better Outcomes; Phase 1 Study Results of Selinexor Combination Therapy for Multiple Myeloma Patients; and the Latest from the ASCO Sessions in the Cancer News Source

Personalized Medicine Leads to Better Outcomes; Phase 1 Study Results of Selinexor Combination Therapy for Multiple Myeloma Patients; and the Latest from ASCO Sessions in the Cancer News Source

– Newswise

NCCN Awards Research Grants to Eight Investigators to Support Clinical and Pre-Clinical Studies of Mirvetuximab Soravtansine in Various Cancers

The NCCN Oncology Research Program has awarded research grants to eight investigators to study the effectiveness of mirvetuximab soravtansine in folate receptor alpha-positive cancers.

– National Comprehensive Cancer Network® (NCCN®)

New Drug "Retrains" Immune System to Fight Aggressive Bladder Cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology (ASCO).

(Embargo expired on 05-Jun-2016 at 07:30 ET)

– NYU Langone Medical Center

Study Suggests Action Required to Minimise Heart Failure in Breast Cancer Survivors

Despite the known toxic effects of chemotherapy on the heart, the majority of women undergoing breast cancer treatment are not getting the recommended follow-up heart scans, according to research presented at the British Cardiovascular Society (BCS) Conference in Manchester.

(Embargo expired on 05-Jun-2016 at 19:05 ET)

British Cardiovascular Society Conference, June-2016

– British Heart Foundation (BHF)

Novel Targeted Drug Shows Promise Against Advanced Small Cell Lung Cancer

The experimental “smart-bomb” drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer, according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering researcher at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

(Embargo expired on 05-Jun-2016 at 07:30 ET)

2016 American Society of Clinical Oncology (ASCO) Annual Meeting

– Memorial Sloan Kettering Cancer Center

MD Anderson Researchers Highlight Advances in Gynecologic Cancer Treatments

Advances that could change gynecologic cancer standard–of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center’s Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO).

 • Image(s) embedded •  (Embargo expired on 05-Jun-2016 at 10:45 ET)

– University of Texas M. D. Anderson Cancer Center

Nivolumab Immunotherapy Helps Patients with Advanced Bladder Cancer

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug’s target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

 • Image(s) embedded •  (Embargo expired on 05-Jun-2016 at 09:00 ET)

– University of Texas M. D. Anderson Cancer Center

Nivolumab Shows Promise in First-Ever Trial for Patients with Refractory, Metastatic Anal Cancer

In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint blockade nivolumab shows promise for the majority of patients with squamous cell carcinoma of the anal canal (SCCA).

 • Image(s) embedded •  (Embargo expired on 05-Jun-2016 at 09:00 ET)

– University of Texas M. D. Anderson Cancer Center

Study Shows Why Immune-Boosting Therapy Doesn't Work for Everyone with Widespread Melanoma

Patients who don’t respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to study results presented at the annual meeting of the American Society for Clinical Oncology (ASCO) on June 4 in Chicago.

(Embargo expired on 04-Jun-2016 at 14:15 ET)

– NYU Langone Medical Center

MD Anderson Study Identifies Significant Cost Differences Between Breast Cancer Chemotherapy Regimens

Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center.

 • Image(s) embedded •  (Embargo expired on 04-Jun-2016 at 17:45 ET)

– University of Texas M. D. Anderson Cancer Center

Rucaparib Shows Clinical Benefit in Pancreatic Cancer Patients with BRCA Mutation

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation.

(Embargo expired on 04-Jun-2016 at 09:00 ET)

ASCO

– Perelman School of Medicine at the University of Pennsylvania

ASCO: Hispanic and Black Young Adult Cancer Patients More Likely to Die of Their Disease

Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2016.

 • Image(s) embedded •  (Embargo expired on 04-Jun-2016 at 13:00 ET)

ASCO 2016

– University of Colorado Cancer Center

Moffitt Cancer Center Finds Radiation Therapy with Pembrolizumab, Bevacizumab Safe for Recurrent High-Grade Glioma Patients

Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients.

– Moffitt Cancer Center

Researchers Find Up to One-Quarter of Lung Cancer Patients May Be Ineligible for Immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center has found.

 • Image(s) embedded • 

JAMA Oncology-June-2016

– UT Southwestern Medical Center

Wnt Stem Cell Signaling Pathway Implicated in Colorectal Cancer in Patients Under 50

At ASCO 2016: University of Colorado Cancer Center study shows that younger colorectal cancer patients are more likely to have alterations in genes involved in what is known as the Wnt signaling pathway, a system of communication that drives the growth, survival and proliferation of cancer stem cells.

 • Image(s) embedded • 

ASCO 2016

– University of Colorado Cancer Center

As Colorectal Cancer Rate Falls, Diagnosis of Late-Stage Cancer in Young Patients Is Up

CU Cancer Center presented at ASCO 2016 finds that in Colorado patients over 50, the rate of CRC is falling at 2.5 percent per year while the rate of CRC in patients under 50 is rising at 0.8 percent per year. The increase in incidence appeared to be driven mostly by an increase in late-stage CRC in the under-50 population with an increase of 2.4 percent per year from 2003 through 2013.

 • Image(s) embedded • 

ASCO 2016

– University of Colorado Cancer Center

Direct Patient Engagement Through Social Media Speeds Recruitment to Cancer Research Study

A crowd-sourcing strategy aimed at accelerating research into metastatic breast cancer has registered more than 2,000 patients from all 50 states in its first seven months, report researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard at the American Society of Clinical Oncology Annual Meeting.

 • Image(s) embedded • 

American Society of Clinical Oncology Annual Meeting

– Dana-Farber Cancer Institute

Lenalidomide Maintenance Therapy Improves Overall Survival for Patients with Multiple Myeloma

Lenalidomide maintenance following stem cell transplant now a standard of care for people with multiple myeloma

American Society of Clinical Oncology (ASCO) 52nd Annual Meeting

– Roswell Park Cancer Institute

Doctors Unleash New Weapon to Fight Pediatric Neuroblastoma

After the first year of receiving the novel treatment combination, 9 out of 17 children with relapsed neuroblastoma saw either a complete or partial remission — a 53 percent response rate compared to the typical 10 to 12 percent response rate.

(Embargo expired on 03-Jun-2016 at 16:30 ET)

– University of Michigan Health System

Investigational Immunotherapy Drug Shrinks Tumors in High-Risk Neuroblastoma Patients

St. Jude Children’s Research Hospital investigators report promising preliminary results at the annual meeting of ASCO for an experimental monoclonal antibody when combined with chemotherapy for newly diagnosed patients.

 • Image(s) embedded • 

– St. Jude Children's Research Hospital

Cancer Patients Miss Appointments, Prescriptions Due to Inability to Afford Care

Researchers report preliminary findings at the American Society of Clinical Oncology Annual Meeting 2016 that 26 percent of a survey of adult cancer patients reported they paid more for medical care than they could afford. Those patients also reported missing appointments and prescriptions because of affordability issues.

ASCO Annual Meeting, June-2016

– University of North Carolina Health Care System

Counseling Patients at Risk for Cancer Over the Phone Reduces Costs and Access Burdens, Penn Study Finds

Delivering genetic test results to patients at risk for cancer-causing genetic mutations over the phone helps to ease cost and transportation burdens and, compared to receiving results in person, does not cause patients additional stress, according to a new study from the Abramson Cancer Center of the University of Pennsylvania which will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (abstract 1502).

American Society of Clinical Oncology Annual Meeting

– Perelman School of Medicine at the University of Pennsylvania

Study Reveals Insights Into Protein Linked to Cancer and Alzheimer’s Disease

Cancer and Alzheimer's disease drugs target specific proteins, blocking or inhibiting their natural interactions, which may be in overdrive. The traditional drug design process typically assumes the protein shapes are static. But tradition turns out to be too limiting, according to new research from the University of Notre Dame.

 • Image(s) embedded • 

Structure

– University of Notre Dame

Moffitt Researchers Report Improved Progression-Free Survival and Responses Rates for Lutathera Over Octreotide

Moffitt Cancer Center will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

– Moffitt Cancer Center

Diabetes Drug Metformin Holds Promise for Cancer Treatment and Prevention, Penn Studies Find

Use of Metformin – commonly used as the front-line treatment for type 2 diabetes – improves survival for some breast cancer patients, and shows promise as a treatment for patients diagnosed with endometrial hyperplasia, according to the results of two new studies presented by researchers from the Perelman School of Medicine at the University of Pennsylvania at the American Society of Clinical Oncology (ASCO) Annual Meeting

American Society of Clinical Oncology (ASCO) Annual Meeting

– Perelman School of Medicine at the University of Pennsylvania

Latest Penn Studies of Personalized Cell Therapies Define Optimal Doses

More precise dosing methods and cellular engineering techniques show promise in the effort to improve treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania and The Children’s Hospital of Philadelphia which will be presented during the 2016 American Society of Clinical Oncology Annual Meeting.

American Society of Clinical Oncology

– Perelman School of Medicine at the University of Pennsylvania

Bacteria Found in Female Upper Reproductive Tract, Once Thought Sterile

In a preliminary finding (abstract 5568) presented Monday, June 6, at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, researchers revealed they have found bacteria in the upper female reproductive tract.

 • Image(s) embedded • 

ASCO Annual Meeting, May-2016

– University of North Carolina Health Care System

Cancer Cell Immunity in the Crosshairs: Worth the Expense?

It's time to say goodbye to ineffective and costly cancer treatments. Japanese scientists have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient.

 • Image(s) embedded • 

Nature

– Kyoto University

Mount Sinai Researchers Present Findings at 2016 ASCO Conference

Findings in Blood-Based Biomarkers for Prostate Cancer, Vaccines for Malignant Melanoma and Solid Tumors, Racial Differences in Aggressive Breast Cancers Presented at 2016 ASCO Conference

– Mount Sinai Health System

Novel Compound Shows Promise Against Breast Cancer

A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.

(Embargo expired on 02-Jun-2016 at 12:00 ET)

– Ohio State University

Room for Improvement in End-of-Life Care, Rethinking Hospital Alarms and more in the Healthcare News Source

Get the latest research and features in healthcare, including hospital administration, patient care, and health economics in Newswise's Healthcare News Source.

– Newswise

Fighting Advanced Thyroid Cancer with Immunotherapy

As the chance of being diagnosed with thyroid cancer has risen in recent years, an investigator at Rutgers Cancer Institute of New Jersey and colleagues are exploring the impact of the immunotherapy drug pembrolizumab on advanced disease. Updated results of their research will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

 • Image(s) embedded • 

ASCO Annual Meeting 2016

– Rutgers Cancer Institute of New Jersey

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows

A new Moffitt Cancer Center study being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published in The Lancet Oncology shows that utilizing the immunotherapeutic agents nivolumab and ipilimumab could lead to more effective treatment options for SCLC patients who fail initial therapy.

– Moffitt Cancer Center

UCLA, Cleveland Clinic and UCSD Collaboration Demonstrates Potential Treatment Breakthrough for Advanced Brain Cancer

Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with recurrent glioblastoma.

 • Image(s) embedded •  (Embargo expired on 01-Jun-2016 at 14:00 ET)

Science Translational Medicine

– University of California, Los Angeles (UCLA), Health Sciences

Mount Sinai Researchers Report Clinical Utility of Personalized Medicine Program for Cancer Patients

Integrated genomic profiles reveal significantly more actionable mutations than targeted cancer panels

– Mount Sinai Health System

Imaging Biomarker Distinguishes Prostate Cancer Tumor Grade

Physicians have long used magnetic resonance imaging (MRI) to detect cancer but results of a University of California San Diego School of Medicine study describe the potential use of restriction spectrum imaging (RSI) as an imaging biomarker that enhances the ability of MRI to differentiate aggressive prostate cancer from low-grade or benign tumors and guide treatment and biopsy.

 • Image(s) embedded • 

Clinical Cancer Research

– University of California, San Diego Health Sciences

Investigators From Montefiore and Einstein to Present Data at American Society of Clinical Oncology Annual Meeting

Montefiore/Einstein investigators present new data at ASCO meeting, including biomarkers for neuroendocrine therapies, benefits of immunotherapy for African American men with prostate cancer.

– Montefiore Health System

Clinical Trial Launched to Test Use of MRI to Improve Prostate Cancer Diagnosis and Management

The Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects.

– Ontario Institute for Cancer Research

The Medical Minute: Surviving Cancer Can Bring New Challenges

Millions of adults and children across the U.S. identify as cancer survivors. Beating cancer can transform someone’s life and lead to a new sense of gratitude – but it can also usher in a range of physical and emotional challenges.

– Penn State Milton S. Hershey Medical Center

Cancer Studies Should Include Overweight, Elderly Mice

Saint Louis University's article in "Trends in Immunology" explains why using a more accurate animal model could improve cancer research.

 • Image(s) embedded • 

Trends in Immunology, June 2016

– Saint Louis University Medical Center

UofL Professor of Surgery Named Editor-in-Chief of Prestigious Scientific Journal

Susan Galandiuk, M.D., professor in the Department of Surgery at the University of Louisville, has been named editor-in-chief of Diseases of the Colon & Rectum, the scientific journal of The American Society of Colon and Rectal Surgeons.

 • Image(s) embedded • 
Expert(s) available

– University of Louisville

Announcements

MD Anderson and Bristol-Myers Squibb Announce New Research Collaboration in Immuno-Oncology Focused on Lung Cancer

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology agents Opdivo (nivolumab) and Yervoy (ipilimumab) to treat early- and advanced-stage lung cancer patients.

 • Image(s) embedded • 

– University of Texas M. D. Anderson Cancer Center

Genomic Data Commons at University of Chicago Heralds New Era of Data Sharing for Cancer Research

The Genomic Data Commons (GDC), a next-generation platform that enables unprecedented data access, analysis and sharing for cancer research, publicly launched at the University of Chicago on June 6, opening the door to discoveries for this complex set of diseases.

 • Image(s) embedded • 

– University of Chicago Medical Center

Meridian Health to Offer Cancer Survivorship Event on June 11, 2016

Free event to focus on living a healthier life during and after cancer treatment.

– Meridian Health

More Patients Can Now Enroll in Clinical Trials Through Meridian Cancer Care Thanks to Community Support

More than 325 guests recently gathered at Eagle Oaks Country Club for Meridian Health Foundation’s inaugural BuildingHOPE Benefit to support oncology research through Meridian Cancer Care. Thanks to the generosity of sponsors and attendees, proceeds from the event will offset costs so that additional oncology patients can enroll in clinical trials through Meridian Cancer Care.

– Meridian Health

Dana-Farber President to Receive SPARK! Award for Health Promotion and Education

The Albert Schweitzer Fellowship (ASF) announced its selections for the 2016 SPARK! Awards. Edward J. Benz, Jr., MD, President and CEO of Dana-Farber Cancer Institute, will receive the 2016 Schweitzer Clarion Award for Health Promotion and Education

 • Image(s) embedded • 

– Dana-Farber Cancer Institute

Two TSRI Chemists Named Finalists for Blavatnik Awards

Matthew Disney, professor on the Florida campus of The Scripps Research Institute (TSRI), and Phil Baran, Darlene Shiley Professor of Chemistry on the California campus of TSRI, have been named chemistry finalists for the 2016 Blavatnik National Awards for Young Scientists.

 • Image(s) embedded • 

– Scripps Research Institute

CU Cancer Center’s Paul Bunn, Jr., MD, FASCO, Earns ASCO David A. Karnofsky Memorial Award

Paul Bunn, Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting.

 • Image(s) embedded • 

– University of Colorado Cancer Center

$750,000 Gift to Benefit Cancer Research at UNM Comprehensive Cancer Center

The Estate of Dana C. Wood and the Dana C. Wood Revocable Trust have provided a $750,000 gift to The University of New Mexico Comprehensive Cancer Center. The UNM Comprehensive Cancer Center will use the gift and state matching funds to create a faculty endowment that Olivier Rixe, MD, PhD, will hold. Rixe is an international expert in early phase clinical trials.

– University of New Mexico Comprehensive Cancer Center

New NCCN Imaging Appropriate Use Criteria Resources Help Assure Patients Receive Best Cancer Care Available

New NCCN Imaging Appropriate Use Criteria Compendium provides a single access point for all imaging recommendations within the NCCN Guidelines

– National Comprehensive Cancer Network® (NCCN®)

Cancer Research Institute Celebrates Fourth Annual Cancer Immunotherapy Month™ in June

Month-long educational and awareness initiative designed increase public awareness of the potential of cancer immunotherapy to treat and potentially cure all cancers.

 • Image(s) embedded • 

– Cancer Research Institute

Otolaryngologist Amy Pittman, MD, Specialist In Reconstructive Surgery, Joins Loyola

Amy Pittman, MD, an otolaryngologist who specializes in microvascular head and neck reconstructive surgery has joined Loyola Medicine. Dr. Pittman is an assistant professor in the department of otolaryngology of Loyola University Chicago Stritch School of Medicine. She is board certified in otolaryngology.

 • Image(s) embedded • 

– Loyola University Health System

Expert Pitch

Georgetown Data Scientist Comments on Biden's Announcement on Open Genomics Database

– Georgetown Lombardi Comprehensive Cancer Center

Extending Anti-Estrogen Therapy by Five Years Helps Breast Cancer Patients

– Loyola University Health System

AVAILABLE FOR INTERVIEW Comment on Vice President Joe Biden’s Moonshot Address at ASCO *** Monday, June 6, 3:00 PM ***

 • Image(s) embedded • 

– New York-Presbyterian Hospital

Progress Against the Rare Cancer That Struck Oliver Sacks

 • Image(s) embedded • 

– University of Utah Health Sciences

Cancer-Fighting 'Trojan Horse' Sparks Hope in Human Trials

 • Image(s) embedded • 

– Houston Methodist

City of Hope Experts Available to Comment on Embargoed Studies Being Presented at ASCO on New Research Developments.

– City of Hope

German researchers on Wednesday presented a “Trojan horse” method of attacking cancer - Experts Needed

– Newswise Trends

subscribe/unsubscribe :: edit my preferences
© 2016 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us